Partners

Collaborative for the Economics of Psychedelics

HSI is a partner of the Collaborative for the Economics of Psychedelics (CEP), of which D. Elliot Marseille is also the founding director. CEP is a network of health economists dedicated to achieving the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, CEP seeks to enhance clinical outcomes, increase efficiency of service delivery, and increase access to these promising therapies for everyone who can benefit. Current projects include consultation with the Multidisciplinary Association for Psychedelic Studies (MAPS) in modeling the economics of MDMA-assisted psychotherapy for the treatment of severe PTSD; with the Usona Institute in analyzing the cost-effectiveness of psilocybin-assisted therapy for major depression; and with John Hopkins University on the cost-effectiveness of psilocybin-assisted therapy for tobacco cessation. CEP is also collaborating with Phaneros on an analysis of changes in health care utilization in conjunction with trials of MDMA and psilocybin in Brazil.

Center for Global Health Delivery, Diplomacy and Economics (CGHDDE)

CEP is a project of the UCB / UCSF Center for Global Health Delivery, Diplomacy and Economics. CGHDDE partners with governments, research institutions, and other organizations in the global health sector to catalyze the transformation of global health policy, systems and services. CGHDDE aims to improve the implementation of existing programs and help leaders around the world better design, manage, and govern contextually appropriate health programs, systems, and policies. Investigators at the Center achieve this by studying the means by which effective interventions are defined and implemented in various contexts and drawing on the lessons learned through our research and work. The Center brings tremendous technical expertise, rigorous research and evaluation experience, and leadership to drive evidence-based systemic change.

Multidisciplinary Association for Psychedelic Studies (MAPS)

MAPS has been a leader in catalyzing the renaissance of clinical research on the therapeutic potential of psychedelics. In addition to its broad clinical research agenda covering many psychedelic materials and psychiatric medications, MAPS wide range of contributions including developing training programs for psychedelic therapists, advocacy, and laying the foundation for MDMA to be an FDA-approved medication to treat PTSD. HSI and CEP has consulted with MAPS on the cost-effectiveness of MDMA-assisted therapy for PTSD, leading to the first published paper on the economics of a DEA Schedule 1 compound to treat a mental health disorder. Current consultation focuses on providing the economic analyses needed for approval of MDMA-assisted therapy by European regulatory agencies.

Usona Institute

The Usona Institute is a non-profit medical research organization conducting pre-clinical and clinical trials to develop the use of psilocybin and other psychedelic materials to treat major depression. The institute was founded in 2014 by Bill Litton, and us based in Madison Wisconsin. HSI and CEP have consulted with Usona on developing a cost-effectiveness model for psilocybin therapy, and I collaboration with Avalon Health Economics , developing a knowledge based on the medical costs of treating depression.

Phaneros Institute

Based in Sao Paolo, Brazil, the Phaneros Institute was founded by its Director Eduardo Schenberg, a neuroscientist psychedelic therapist trainer and entrepreneur. His research interests focus on the neurological and phenomenological impact of a wide range of psychedelic materials. Current projects include planning for 10 community-based trials of psilocybin and MDMA to treat PTSD in range of population subgroups such as health care workers ad indigenous people. In partnership with Phaneros and the health economist Dr. Rudi Rocha, CEP is planning for a range of cos-effectiveness and other economic evaluations of these therapies in the Brazilian context.